On April 28, 2025, UGenome AI team mates Ayse ULGEN, PhD, MGM, Peter Bannister, and Zachary S. Brooks, PhD, EMBA gave a talk to Nottingham Trent University entitled: “UGenome AI’s promise to revolutionize the pharmacogenomics research – ProPEx.”
UGenome AI and Nottingham Trent University collaborate to investigate metabolic related biomarkers and biochemistry to help predict which disease respond best to which set of medications based on an individual’s genetic profile.
Multiple genes can be involved in the how people respond to medications (pharmacogenomics) such as CYP2B6, CYP2C1, CYP2C9, CYP2D6, CYP3A4, CYP3A5, NUDT15, SLCO1B1, TPMT, and VKORC1
Learn more about UGenome.
Personalized Medication Service, ProPEx, or contact UGenome. You can also find case studies for UGenome’s bioinformatics services Metabolite Identification, Bone Metastasis Risk Analysis in Breast Cancer, Survival Analysis with gene signatures in cancer
#ugenome, #ugenomeai, #genetics, #pharmacogenetics, #genomicmedicine, #sequencing, #datascience, #lifesciences, #bioinformatics, #biostatistics, #pharma, #bullpen, #NVIDIAInception, #foundershub